Neurology Exchange

September 20, 2022 – September 22, 2022

Virtual

CME/CE
swoosh
swoosh

AGENDA

*All sessions listed in Eastern time. Agenda subject to change. 

ENHANCE YOUR EXPERIENCE WITH MEDCHALLENGE!

This event features MedChallenge, a new feature from Medscape that allows you to go head-to-head against your peers in a series of medical questions. Earn points, deepen your knowledge, and fight for the top spot on the leaderboard!

Callout Info for program

PART I

PART II

 

LEARNING OBJECTIVES

Upon completion of Session I, participants will:

    • Increase competence in utilizing the McDonald criteria for the diagnosis of Multiple Sclerosis (MS) 
    • Increase knowledge of factors that impact the selection of an initial disease-modifying therapy (DMT) for the management of MS 
    • Increase competence in the ability to personalize the initial selection of a DMT for the management of MS 
    • Increase knowledge of clinical data for pharmacotherapies for the management of progressive forms of MS 
    • Increase knowledge of the mechanistic differences between progressive and relapsing/refractory forms of MS 
    • Increase knowledge of common symptomatic manifestations of MS 
    • Increase knowledge of therapeutic options for the management of specific symptomatic manifestations of MS 
    • Demonstrate greater confidence when collaborating with the interprofessional team to manage specific symptomatic manifestations of MS 

 

SESSION CHAIR


 

 

LEARNING OBJECTIVES

Upon completion of Session II, participants will: 

    • Increase knowledge of differentiating factors associated with neuromuscular conditions 
    • Increase knowledge of clinical data for new and emerging therapies for the management of neuromuscular conditions 
    • Increase knowledge of the pathophysiologic basis of neuromuscular conditions 

 

SESSION CHAIR


 

 

LEARNING OBJECTIVES

Upon completion of Session III, participants will:

    • Increase knowledge of factors involved in the identification of patients with stroke for thrombolytic therapy
    • Increase knowledge of clinical data for thrombolytic therapies studied for the management of stroke
    • Increase knowledge of the guideline-recommended use of endovascular treatment for the management of stroke
    • Increase knowledge of clinical data on long-term patient outcomes associated with the use of endovascular therapy for the management of stroke
    • Increase knowledge of recent clinical data examining the effect of use of stroke therapeutics outside of the established timeline for use

SESSION CHAIR


 

 

LEARNING OBJECTIVES

Upon completion of Session IV and the Keynote Presentation, participants will: 

    • Increase knowledge in the types of information that is derived from an electroencephalogram (EEG) for the assessment of epilepsy
    • Increase competence in the ability to use EEG to differentiate common forms of epilepsy 
    • Increase knowledge of the primary goals of treatment for epilepsy 
    • Increase competence in the ability to personalize the selection of an initial antiseizure medication for the management of epilepsy 
    • Increase knowledge of factors involved in the decision to make a change to the initial treatment plan for epilepsy 
    • Increase competence in the ability to modify the treatment plan in patients with epilepsy 
    • Increase knowledge of the criteria associated with treatment-resistant epilepsy 
    • Increase knowledge of the factors involved in the selection of specific surgical approaches for the management of treatment-resistant epilepsy 
    • Increase knowledge of communication factors involved in the transition of a patient with pediatric-onset epileptic encephalopathies from pediatric to adult care 
    • Increase competence in the ability to assess patients with pediatric-onset epileptic encephalopathies who have transitioned from pediatric to adult care 
    • Increase knowledge of clinical data for the use of anti-seizure medications (ASMs) for the management of pediatric-onset epileptic encephalopathies among adult patients 
    • Increase confidence when collaborating with the interprofessional team to transition to adult care for patients with epileptic encephalopathies
    • Have increased knowledge regarding the impact of a diagnosis of neurological disease on patients and caregivers to facilitate better communication

SESSION CHAIR


 

 

LEARNING OBJECTIVES

Upon completion of Session V, participants will:

    • Increase knowledge of appropriate pharmacotherapies to consider at different stages of Parkinson disease
    • Increase knowledge of factors involved in the identification of patients with Parkinson disease who are candidates for on-demand therapies
    • Increase knowledge of clinical data on the use of on-demand therapies for the management of Parkinson disease
    • Increase knowledge of factors involved in the identification of patients who are candidates for device-based therapies for the management of Parkinson disease
    • Increase knowledge of factors that differentiate device-based approaches for the management of Parkinson disease

SESSION CHAIR


 

LEARNING OBJECTIVES

Upon completion of Session VI, participants will:

    • Increase knowledge of clinically relevant tools to assess cognitive impairment in older adults 
    • Increase competence in the ability to accurately diagnose early stages of Alzheimer's disease
    • Increase knowledge of the mechanism of action of emerging pharmacotherapies for the management of Alzheimer's disease 
    • Increase knowledge of clinical trial data for emerging pharmacotherapies for the management of Alzheimer
    • Increased knowledge regarding the recent trial data on emerging interventional techniques
    • Greater competence related to selection of appropriate patients for emerging interventional techniques

SESSION CHAIR


 

LEARNING OBJECTIVES

Upon completion of Session VII, participants will:

  • Increased knowledge regarding
    • Increase knowledge of clinical data for calcitonin gene-related peptide (CGRP)-targeted therapies studied for the management of migraine
    • Increase knowledge of clinical factors for the identification of patients who may be candidates for a CGRP-targeted therapy for the management of migraine
    • Increase competence in the selection of an appropriate CGRP-targeted therapy for the management of migraine
    • Increase knowledge of factors involved in the identification of patients who are candidates for a non-oral acute migraine therapy
    • Increase competence in the selection of an appropriate non-oral acute therapy for the management of migraine
    • Increase knowledge of clinical data for devices used for the management of migraine 
    • Increase knowledge of factors involved in the identification of patients who may be candidates for a device-based therapy for the management of migraine

SESSION CHAIR


 

LEARNING OBJECTIVES

Upon completion of Session VIII, participants will:

    • Increase knowledge of the pathophysiologic basis of muscular dystrophies
    • Increase knowledge of strategies to reduce the time to diagnosis of muscular dystrophies
    • Increase knowledge of clinical data for new and emerging therapies for the management of muscular dystrophies
    • Increase knowledge of strategies to support patient access of timely care following a diagnosis of spinal muscular atrophy (SMA)
    • Increase knowledge of clinical trial data for therapies used for the management of SMA
    • Increase competence in the development of a comprehensive treatment plan for the management of adults with SMA

SESSION CHAIRS


 

LEARNING OBJECTIVES

Upon completion of Session IX, participants will:

  • Increased knowledge regarding
    • Increase knowledge of factors involved in the successful use of telemedicine to deliver high-quality neurologic care
    • Increase knowledge of the roles and responsibilities of the healthcare team for optimal care via telemedicine 

      Increase knowledge of data indicating disparities in care among patients of diverse racial or ethnic backgrounds

    • Increase knowledge of the roles and responsibilities of the healthcare team in ensuring equitable care for neurology patients

SESSION CHAIR